Blitz India Business
NEW DELHI: A licensing window closes on Friday. On the other side of it are three technologies developed inside the Indian Council of Medical Research, each finished enough to be manufactured and none of them, yet, a product.
The Council has invited expressions of interest for transfer of technology on a dual-tube one-step RT multiplex PCR dengue assay, a multiplex qPCR kit that distinguishes Giardia lamblia from Entamoeba, and a cell culture plate with interconnected wells. All three carry a last date of submission of 4 September 2026. For an industry reader the interesting fact is not the science; it is the structure of the offer.
What a transfer-of-technology invitation actually is
The intellectual property stays with the Council. The licensee receives the technology and takes on the manufacture, the regulatory file and the distribution. For the two diagnostic kits that file runs through the Central Drugs Standard Control Organisation, and that approval is not part of what is being transferred. The Council operates a dedicated route for these arrangements, Patent Mitra, and the commercial terms sit in each call document rather than in the notice.
The addressable market is not small. Dengue is endemic across most of India and serotype-level information changes clinical management; intestinal parasite testing is currently done overwhelmingly by microscopy in the public system. Both are high-volume, low-value tests — precisely the segment where an Indian-designed kit competes on landed cost rather than on novelty, and where import substitution is a matter of arithmetic rather than of sentiment.
The intellectual property stays with the Council. The manufacture, the regulatory file and the distribution do not.
The demand side is being built too
Two other calls open on the Council’s board belong to the same commercial picture. Proposals are invited for setting up Viral Research and Diagnostic Laboratories in medical colleges, hospitals and medical institutions, closing 30 September 2026, and expressions of interest for Technical Resource Centres in the North-Eastern States, closing 15 September. Every laboratory added to that network is an installed base for exactly the class of assay being licensed this week. A manufacturer reading only the transfer notice is reading half the proposition.
What India gains. Molecular diagnostics are a category India still substantially imports, kit by kit and reagent by reagent. An Indian-designed dengue assay made by an Indian firm displaces that payment, shortens the supply line, and gives the manufacturer a product it can register in other tropical-disease markets where India already supplies medicines. The export logic follows the domestic one: a country that makes its own diagnostics negotiates on health security from a different position than one that queues for them.
Offered only as corrective advice, to help the work move faster: a transfer-of-technology invitation of genuine commercial interest deserves a longer window than a routine tender, and a short technical abstract — sensitivity, specificity, validation stage — on the notice itself rather than only inside the call document. Both would widen the field of firms able to respond within the time given.